<DOC>
	<DOCNO>NCT00587587</DOCNO>
	<brief_summary>This pilot study assess safety efficacy Apligraf heal recurrence keloid post surgical shave excision patient clinically diagnosed keloid .</brief_summary>
	<brief_title>A Pilot Study Apligraf Treatment Prevention Recurrence Excised Keloids</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Keloid</mesh_term>
	<criteria>Subject 18 65 year age . Subject legal guardian read , understood , sign appropriate Institutional Review Board ( IRB ) approve informed consent , photography release form HIPAA consent language . Subject 1 keloid measure 1 cm2 40 cm2 assess Investigator , present least 6 month Beausang Scar scale combine score 5 great . Subject male female must document negative urine pregnancy test child bear potential . Sexually active female must practice medically proven form contraception course study period . Subject and/or legal guardian must able willing follow study procedure instruction . Subject and/or legal guardian must able willing return followup study visit . Subject agree use keloid medication injection treatment four week prior Day 0 . Subject agree use keloid treatment duration study . Subject otherwise healthy assess determined Investigator Subject suffer condition likely require medical attention , include administration treatment opinion Investigator could influence result study . Subject systemic condition like uncontrolled diabetes mellitus ( glycosylated hemoglobin , HbA1C &gt; 10 % ) , cancer ( biopsy confirm active malignancy ) , positive HIV test , disorder ( ) may compromise wound healing . Subject suffer abnormal skin condition affect area usually associate keloid psoriasis , eczema . Subject currently receive topical systemic steroid medication therapy within past four week affect course keloid and/or evaluability . Inhaled steroid therapy acceptable . Subject presence acute infection area intend treatment . Subject know hypersensitivity bovine collagen component Apligraf agarose ship medium . Subject lactate pregnant ( positive result determine urine testing ) . Subject liver ( ALT/SGPT , ALP , AST/SGOT , bilirubin , albumin , total protein , LDH ) and/or renal function ( BUN creatinine ) test &gt; 2 x upper limit normal ( ULN ) . Subject previously enrol wound investigational device study disease within past four week . Subject receive investigational drug biological treatment within past three month . Subject previously treat Apligraf , Dermagraft cell therapy target keloid site . Subject history alcohol substance abuse within previous year , could interfere study compliance inability attend schedule study visit compliance home dressing change . Subject history anaphylaxis . Subject , opinion Investigator , reason list , able complete study per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>